Based on this rationale, HDAC3 loss-of-function or selective HDAC3 inhibition has been recently shown to induce strong anti-lymphoma effects by increasing H3K27ac in CREBBP-mutant lymphoma while those effects are modest in CREBBP wild-type tumors [6, 11]. This evidence concerns the gene CREBBP and lymphoma.